PhD Scientific Days 2025

Poster Session II. - G: Pharmaceutical Sciences and Health Technologies

Mesenchymal Stem Cell Derived Extracellular Vesicles Functional Study and Their Utilization for the Reduction of Chemotherapeutics Caused Cardiotoxicity

Előadó neve

Rácz Richárd, MSc

Neptun code

etgd69

Előadó munkahelye

Semmelweis University, Faculty of Medicine, Department of Pharmacology and Pharmacotherapy

Előadó telefonszáma

06304674552

Előadó e-mail címe

racz.richard@semmelweis.hu

Az előadás címe

Mesenchymal Stem Cell Derived Extracellular Vesicles Functional Study and Their Utilization for the Reduction of Chemotherapeutics Caused Cardiotoxicity

Szerző(k) neve és munkahelye

Rácz Richárd, MSc¹, Hambalkó Szabolcs¹, Dr. Giricz Zoltán¹

1: Semmelweis University, Faculty of Medicine, Department of Pharmacology and Pharmacotherapy

Bemutatás módja

Poszter

Szekció

Poster Session II. - G: Pharmaceutical Sciences and Health Technologies

Language of the presentation

English

Preferred session

Pharmaceutical Sciences and Health Technologies

Összefoglaló szövege

Mesenchymal Stem Cell Derived Extracellular Vesicles Functional Study and Their Utilization for the Reduction of Chemotherapeutics Caused Cardiotoxicity

Introduction:
Chemotherapeutic agent which are widely used in the treatment of various cancers can cause cardiotoxic side effects which limit their clinical efficacy and compromise patient health.
Mesenchymal stem cells (MSCs) have gained significant attention for their regenerative potential, partly attributed to their secretion of extracellular vesicles (EVs). MSC-derived EVs carry bioactive molecules, that can modulate cellular behaviour, promote tissue repair, and reduce inflammation. Recent studies have demonstrated the cardioprotective properties of MSC EVs, suggesting their potential to alleviate the cardiotoxic effects of a wide range of chemotherapeutics.

Aims:
We aim to validate and understand the therapeutic potential of MSC EVs in counteracting the cardiotoxicity induced by doxorubicin, 5-fluorouracil, trastuzumab, and lapatinib. Specifically, we explore the molecular mechanisms by which MSC EVs exert their protective effects, including modulation of oxidative stress, inhibition of apoptosis, changes in mitophagy and autophagy, and promotion of cardiac tissue regeneration.

Methods:
We work in vitro with AC16 and iUC-MSC cell lines, while utilizing many different methodologies for end-point measurements such as: Viability, cytotoxicity assays, Western blots, PCR/RT-PCR, flowcytometry.

Result:
We have already succeeded in reducing the cardiotoxic effect of Compound A, Compound B and Compound C using UC-MSC EVs. Now we are looking further into the biological changes within the cells (autophagy, mitophagy pathways).

Conclusion:
In conclusion, MSC-derived EVs represent a promising therapeutic strategy for reducing the cardiotoxic side effects of chemotherapeutics. By harnessing the natural regenerative properties of MSC EVs, it may be possible to enhance the safety and efficacy of cancer treatments, providing a vital improvement in patient outcomes.

Funding:
The project was funded by Dr. Giricz Zoltán’s OTKA and the Kompetencia Központ Grant.

Created by Richárd Rácz (racz.richard@semmelweis.hu)
Semmelweis University, Faculty of Medicine, Department of Pharmacology and Pharmacotherapy
My supervisors: Dr. Giricz Zoltán, Hambalkó Szabolcs
This topic is preferred to be presented as a poster.

University

Semmelweis University

Supervisor

Dr. Giricz Zoltán, Hambalkó Szabolcs

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

phd.section.field

in doctoral studies before complex exam (PhD)

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

9121

Start

18:12

End

18:18